Percentage of patients with a diagnosis of exudative age-related macular degeneration, being treated with anti-VEGF agents, with a gain of 1 Snellen line or more (which is equivalent to 0.1 logMAR or more) of visual acuity within the past 12 months compared to pre-treatment. Weighted average of performance rates reported.